Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...
CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better ...
Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.
NewsVoir New Delhi [India] 3 Indraprastha Apollo Hospitals proudly announces the launch of its Heart Valve Clinic a dedicated ...
Indraprastha Apollo Hospitals has launched a Heart Valve Clinic, offering advanced care for heart valve disorders. The clinic boasts cutting-edge technology and a multidisciplinary team for ...
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
The American Heart Association has issued its heart disease and stroke statistical update for 2025, which provides an ...
Foundation has received a generous gift to establish the David & Tara Ruberg HVI Innovation and Research Center of ...
Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...